Furthermore, this method has been applied in a real-world clinical setting to evaluate drug exposure in patients with CF receiving CFTR modulator therapy, which constitutes a first step toward the emerging field of the precision therapy of CFTR disorders. The gene discussed is CFTR; the disease is cystic fibrosis.